PPM1D430, a novel alternative splicing variant of the human PPM1D, can dephosphorylate p53 and exhibits specific tissue expression

Journal of Biochemistry

Volumn 145, Issue 1, 2009, Pages 1-12

  Chuman, Yoshiro ^a   Kurihashi, Wataru ^a   Mizukami, Yohei ^a   Nashimoto, Takehiro ^a   Yagi, Hiroaki ^a   Sakaguchi, Kazuyasu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Alternative splicing variant; p53; Phosphatase; PPM1D; Tissue specific expression

Indexed keywords

MESSENGER RNA; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN P53; PROTEIN PHOSPHATASE MAGNESIUM DEPENDENT 1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; GENE EXPRESSION PROFILING; GENOTOXICITY; HUMAN; HUMAN CELL; IMMUNITY; LEUKOCYTE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SPERMATOGENESIS;

ALTERNATIVE SPLICING; CELL LINE, TUMOR; DNA DAMAGE; GENE EXPRESSION; GENETIC VARIATION; HUMANS; MODELS, GENETIC; PHOSPHOPROTEIN PHOSPHATASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 58149114755     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvn135     Document Type: Article

References (50)

1. Fiscella, M., Zhang, H., Fan, S., Sakaguchi, K., Shen, S., Mercer, W.E., Vande Woude, G.F., O'Connor, P.M., and Appella, E. (1997) Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc. Natl Acad. Sci. USA 94, 6048-6053
2. Takekawa, M., Adachi, M., Nakahata, A., Nakayama, I., Itoh, F., Tsukuda, H., Taya, Y., and Imai, K. (2000) p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J. 19, 6517-6526
3. Lu, X., Nannenga, B., and Donehower, L.A. (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 19, 1162-1174
4. Fujimoto, H., Onishi, N., Kato, N., Takekawa, M., Xu, X.Z., Kosugi, A., Kondo, T., Imamura, M., Oishi, I., Yoda, A., and Minami, Y. (2006) Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ. 13, 1170-1180
5. Oliva-Trastoy, M., Berthonaud, V., Chevalier, A., Ducrot, C., Marsolier-Kergoat, M.C., Mann, C., and Leteurtre, F. (2007) The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene 26, 1449-1458
6. Lu, X., Bocangel, D., Nannenga, B., Yamaguchi, H., Appella, E., and Donehower, L.A. (2004) The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol. Cell 15, 621-634
7. Shreeram, S., Demidov, O.N., Hee, W.K., Yamaguchi, H., Onishi, N., Kek, C., Timofeev, O.N., Dudgeon, C., Fornace, A.J., Anderson, C.W., Minami, Y., Appella, E., and Bulavin, D.V. (2006) Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol. Cell 23, 757-764
8. Lu, X., Ma, O., Nguyen, T.A., Jones, S.N., Oren, M., and Donehower, L.A. (2007) The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12, 342-354
9. Li, J., Yang, Y., Peng, Y., Austin, R.J., van Eyndhoven, W.G., Nguyen, K.C., Gabriele, T., McCurrach, M.E., Marks, J.R., Hoey, T., Lowe, S.W., and Powers, S. (2002) Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat. Genet. 31, 133-134
10. Sinclair, C.S., Rowley, M., Naderi, A., and Couch, F.J. (2003) The 17q23 amplicon and breast cancer. Breast Cancer Res. Treat. 78, 313-322
11. Bärlund, M., Kuukasjärvi, T., Syrjäkoski, K., Auvinen, A., and Kallioniemi, A. (2004) Frequent amplification and overexpression of CCND1 in male breast cancer. Int. J. Cancer 111, 968-971
12. Saito-Ohara, F., Imoto, I., Inoue, J., Hosoi, H., Nakagawara, A., Sugimoto, T., and Inazawa, J. (2003) PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 63, 1876-1883
13. Ehrbrecht, A., Müller, U., Wolter, M., Hoischen, A., Koch, A., Radlwimmer, B., Actor, B., Mincheva, A., Pietsch, T., Lichter, P., Reifenberger, G., and Weber, R.G. (2006) Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J. Pathol. 208, 554-563
14. Mendrzyk, F., Radlwimmer, B., Joos, S., Kokocinski, F., Benner, A., Stange, D.E., Neben, K., Fiegler, H., Carter, N.P., Reifenberger, G. et al. (2005) Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J. Clin. Oncol. 23, 8853-8862
15. Castellino, R.C., De Bortoli, M., Lu, X., Moon, S.H., Nguyen, T.A., Shepard, M.A., Rao, P.H., Donehower, L.A., and Kim, J.Y. (2008) Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J. Neurooncol. 86, 245-256
16. Hirasawa, A., Saito-Ohara, F., Inoue, J., Aoki, D., Susumu, N., Yokoyama, T., Nozawa, S., Inazawa, J., and Imoto, I. (2003) Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin. Cancer Res. 9, 1995-2004
17. Fuku, T., Semba, S., Yutori, H., and Yokozaki, H. (2007) Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathol. Int. 57, 566-571
18. Loukopoulos, P., Shibata, T., Katoh, H., Kokubu, A., Sakamoto, M., Yamazaki, K., Kosuge, T., Kanai, Y., Hosoda, F., Imoto, I., Ohki, M., Inazawa, J., and Hirohashi, S. (2007) Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci. 98, 392-400
19. Bulavin, D.V., Demidov, O.N., Saito, S., Kauraniemi, P., Phillips, C., Amundson, S.A., Ambrosino, C., Sauter, G., Nebreda, A.R., Anderson, C.W., Kallioniemi, A., Fornace, A.J. Jr, and Appella, E. (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet. 31, 210-215
20. Choi, J., Nannenga, B., Demidov, O.N., Bulavin, D.V., Cooney, A., Brayton, C., Zhang, Y., Mbawuike, I.N., Bradley, A., Appella, E., and Donehower, L.A. (2002) Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol. Cell Biol. 22, 1094-1105
21. Bulavin, D.V., Phillips, C., Nannenga, B, Timofeev, O., Donehower, L.A., Anderson, C.W., Appella, E., and Fornace, A.J. Jr (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat. Genet. 36, 343-350
22. Rayter, S., Elliott, R., Travers, J., Rowlands, M.G., Richardson, T.B., Boxall, K., Jones, K., Linardopoulos, S., Workman, P., Aherne, W., Lord, C.J., and Ashworth, A. (2008) A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene 27, 1036-1044
23. Belova, G.I., Demidov, O.N., Fornace, A.J. Jr, and Bulavin, D.V. (2005) Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biol. Ther. 4, 1154-1158
24. Chuman, Y., Yagi, Y., Fukuda, T., Nomura, T., Matsukizono, M., Shimohigashi, Y., and Sakaguchi, K. (2008) Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein Phosphatase PPM1D. Protein Pept. Lett. 15, 938-948
25. Bang, J., Yamaguchi, H., Durell, S.R., Appella, E., and Appella, D.H. (2008) A small molecular scaffold for selective inhibition of Wip1 phosphatase. ChemMedChem 3, 230-232
26. Yamaguchi, H., Durell, S.R., Feng, H., Bai, Y., Anderson, C.W., and Appella, E. (2006) Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cδ, Wip1. Biochemistry 45, 13193-13202
27. Schito, M.L., Demidov, O.N., Saito, S., Ashwell, J.D., and Appella, E. (2006) Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation. J. Immunol. 176, 4818-4825
28. Shreeram, S., Hee, W.K., Demidov, O.N., Kek, C., Yamaguchi, H., Fornace, A.J. Jr, Anderson, C.W., Appella, E., and Bulavin, D.V. (2006) Regulation of ATM/ p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J. Exp. Med. 203, 2793-2799
29. Modrek, B. and Lee, C.J. (2003) Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss. Nat. Genet. 34, 177-180
30. Mironov, A.A., Fickett, J.W., and Gelfand, M.S. (1999) Frequent alternative splicing of human genes. Genome Res. 9, 1288-1293
31. Srebrow, A. and Kornblihtt, A.R. (2006) The connection between splicing and cancer. J. Cell Sci. 119, 2635-2641
32. Moore, M.J. and Silver, P.A. (2008) Global analysis of mRNA splicing. RNA 14, 197-203
33. Takekawa, M., Maeda, T., and Saito, H. (1998) Protein phosphatase 2Ca inhibits the human stress-responsive p38 and JNK MAPK pathways. EMBO J. 17, 4744-4752
34. Terasawa, T., Kobayashi, T., Murakami, T., Ohnishi, M., Kato, S., Tanaka, O., Kondo, H., Yamamoto, H., Takeuchi, T., and Tamura, S. (1993) Molecular cloning of a novel isotype of Mg(2+)-dependent protein phosphatase β (type 2Cβ) enriched in brain and heart. Arch. Biochem. Biophys. 307, 342-349
35. Ohnishi, M., Chida, N., Kobayashi, T., Wang, H., Ikeda, S., Hanada, M., Yanagawa, Y., Katsura, K., Hiraga, A., and Tamura, S. (1999) Alternative promoters direct tissue-specific expression of the mouse protein phosphatase 2Cβ gene. Eur. J. Biochem. 263, 736-745
36. Kusuda, K., Kobayashi, T., Ikeda, S., Ohnishi, M., Chida, N., Yanagawa, Y., Shineha, R., Nishihira, T., Satomi, S., Hiraga, A., and Tamura, S. (1998) Mutational analysis of the domain structure of mouse protein phosphatase 2Cβ. Biochem. J. 332, 243-250
37. Choi, J., Appella, E., and Donehower, L.A. (2000) The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene. Genomics 64, 298-306
38. Danckwardt, S., Neu-Yilik, G., Thermann, R., Frede, U., Hentze, M.W., and Kulozik, A.E. (2002) Abnormally spliced β-globin mRNAs: a single point mutation generates transcripts sensitive and insensitive to nonsense-mediated mRNA decay. Blood 99, 1811-1816
39. Dreumont, N., Maresca, A., Boisclair-Lachance, J.F., Bergeron, A., and Tanguay, R.M. (2005) A minor alternative transcript of the fumarylacetoacetate hydrolase gene produces a protein despite being likely subjected to nonsense-mediated mRNA decay. BMC Mol. Biol. 6, 1
40. Nannenga, B., Lu, X., Dumble, M., Van Maanen, M., Nguyen, T.A., Sutton, R., Kumar, T.R., and Donehower, L.A. (2006) Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol. Carcinog. 45, 594-604
41. Bode, A.M. and Dong, Z. (2004) Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4, 793-805
42. Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., Tamai, K., Tokino, T., Nakamura, Y., and Taya, Y. (2000) p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849-862
43. Lu, X., Nguyen, T.A., Moon, S.H., Darlington, Y., Sommer, M., and Donehower, L.A. (2008) The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 27, 123-135
44. Kim, H.J., Woo, I.S., Kang, E.S., Eun, S.Y., Kim, H.J., Lee, J.H., Chang, K.C., Kim, J.H., and Seo, H.G. (2006) Identification of a truncated alternative splicing variant of human PPARgamma1 that exhibits dominant negative activity. Biochem. Biophys. Res. Commun. 347, 698-706
45. Ito, T., Hozumi, Y., Sakane, F., Saino-Saito, S., Kanoh, H., Aoyagi, M., Kondo, H., and Goto, K. (2004) Cloning and characterization of diacylglycerol kinase iota splice variants in rat brain. J Biol Chem. 279, 23317-23326
46. Watanabe, K., Ozaki, T., Nakagawa, T., Miyazaki, K., Takahashi, M., Hosoda, M., Hayashi, S., Todo, S., and Nakagawara, A. (2002) Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. J. Biol. Chem. 277, 15113-15123
47. Ozaki, T., Watanabe, K., Nakagawa, T., Miyazaki, K., Takahashi, M., and Nakagawara, A. (2003) Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB. Oncogene 22, 3231-3242
48. Liu, G. and Chen, X. (2005) The C-terminal sterile α motif and the extreme C terminus regulate the transcriptional activity of the alpha isoform of p73. J. Biol. Chem. 280, 20111-20119
49. Breuleux, M., Schoumacher, F., Rehn, D., Küng, W., Mueller, H., and Eppenberger, U. (2006) Heregulins implicated in cellular functions other than receptor activation. Mol. Cancer Res. 4, 27-37
50. Yoda, A., Xu, X.Z., Onishi, N., Toyoshima, K., Fujimoto, H., Kato, N., Oishi, I., Kondo, T., and Minami, Y. (2006) Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1. J. Biol. Chem. 281, 24847-24862